MCDA logo

KMA Holding, Inc. (MCDA) Análisis de Acciones

Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

Cotizando a $, KMA Holding, Inc. (MCDA) es una empresa del sector Healthcare valorada en 0. La acción obtiene una puntuación de 50/100, una calificación moderada basada en 9 KPI cuantitativos.

Ultimo analisis: 16 mar 2026
Puntuación de IA de 50/100

KMA Holding, Inc. (MCDA) Resumen de Asistencia Médica y Tuberías

CEORonald Ritter
Sede CentralPompano Beach, US
Año de la oferta pública inicial (OPI)2010

KMA Holding, Inc. specializes in manufacturing and distributing home medical test kits and emergency response mobile hospital units, focusing on early illness detection. Operating within the medical instruments and supplies sector, the company aims to provide accessible diagnostic tools and mobile medical solutions, primarily in the United States.

Procedencia de los datos | Datos financieros Análisis cuantitativo NASDAQ Análisis: 16 mar 2026

Tesis de Inversión

KMA Holding, Inc. presents a speculative investment opportunity within the home medical testing and mobile medical solutions market. The company's focus on early disease detection and mobile emergency response units addresses growing healthcare needs. However, with a market capitalization of $0.00B and a beta of -3.02, the company exhibits high risk and volatility. Revenue generation and profitability remain uncertain. Potential investors should carefully consider the company's OTC market listing, limited financial disclosure, and shell risk detection. Growth depends on successful market penetration and regulatory approvals. The investment thesis hinges on KMA's ability to scale production and distribution effectively.

Basado en las finanzas de FMP y el análisis cuantitativo

Puntos clave

  • KMA Holding, Inc. manufactures home medical test kits for humans and pets, focusing on early disease detection.
  • The company also provides emergency medical response mobile hospital units, offering temporary life support and medical services.
  • KMA Holding operates in the OTC market, which presents unique risks and challenges compared to major exchanges.
  • The company's beta of -3.02 indicates an inverse correlation with the market, suggesting potential for diversification but also higher risk.
  • KMA Holding, Inc. has no dividend yield, indicating that the company is not currently returning profits to shareholders.

Competidores y Pares

Fortalezas

  • Niche market focus on home medical testing and mobile hospital units.
  • Diverse product portfolio including human and pet test kits.
  • Potential for recurring revenue through test kit refills and mobile unit services.
  • Established brand recognition in specific geographic areas.

Debilidades

  • Limited market capitalization and financial resources.
  • Dependence on regulatory approvals for test kit commercialization.
  • High competition from established healthcare companies.
  • OTC market listing increases investment risk.

Catalizadores

  • Upcoming: Potential regulatory approvals for new home medical test kits, expanding market access.
  • Ongoing: Increasing demand for home healthcare solutions due to aging population and rising healthcare costs.
  • Ongoing: Strategic partnerships with healthcare providers and telehealth platforms to enhance distribution.
  • Upcoming: Development and launch of advanced diagnostic technologies to improve test accuracy and usability.
  • Ongoing: Geographic expansion into new markets with unmet needs for home medical testing.

Riesgos

  • Potential: Stringent regulatory requirements and compliance costs impacting profitability.
  • Potential: Rapid technological advancements and product obsolescence reducing market competitiveness.
  • Potential: Economic downturns impacting healthcare spending and consumer demand.
  • Ongoing: High competition from established healthcare companies with greater resources.
  • Ongoing: OTC market listing increases investment risk due to limited financial disclosure and liquidity.

Oportunidades de crecimiento

  • Expansion of Home Medical Test Kit Offerings: KMA Holding can expand its range of home medical test kits to include more comprehensive diagnostic panels and cater to a broader range of health conditions. The global home healthcare market is projected to reach $365 billion by 2028, presenting a significant opportunity for KMA to capture a larger market share. Timeline: 2-3 years.
  • Strategic Partnerships with Healthcare Providers: Collaborating with hospitals, clinics, and telehealth platforms can enhance KMA's distribution network and market reach. These partnerships can facilitate the integration of KMA's home test kits into existing patient care pathways, driving adoption and revenue growth. The telehealth market is expected to grow substantially, offering a synergistic opportunity. Timeline: 1-2 years.
  • Geographic Expansion into New Markets: KMA Holding can explore opportunities to expand its operations beyond the United States and enter international markets with unmet needs for home medical testing and mobile healthcare solutions. Emerging markets with growing healthcare expenditure represent attractive targets. Timeline: 3-5 years.
  • Development of Advanced Diagnostic Technologies: Investing in research and development to create more sophisticated and accurate diagnostic technologies can provide KMA with a competitive edge. This includes exploring innovative biosensors, microfluidics, and data analytics to enhance the performance and usability of its test kits. Timeline: 2-4 years.
  • Leveraging Telemedicine for Remote Monitoring: Integrating its home medical test kits with telemedicine platforms can enable remote patient monitoring and personalized healthcare services. This approach can improve patient outcomes, reduce healthcare costs, and generate recurring revenue streams for KMA. The telemedicine market is experiencing rapid growth, driven by increasing demand for remote healthcare solutions. Timeline: 1-3 years.

Oportunidades

  • Expansion into new geographic markets.
  • Strategic partnerships with healthcare providers and telehealth platforms.
  • Development of advanced diagnostic technologies.
  • Increased demand for home healthcare solutions due to aging population.

Amenazas

  • Stringent regulatory requirements and compliance costs.
  • Rapid technological advancements and product obsolescence.
  • Economic downturns impacting healthcare spending.
  • Product liability claims and recalls.

Ventajas competitivas

  • Specialized product offerings in home medical testing and mobile medical units.
  • Proprietary technology in mobile unit communication systems.
  • Established presence in the niche market of pet home medical testing.
  • First-mover advantage in certain geographic regions.

Acerca de MCDA

Founded in 2000 and based in Pompano Beach, Florida, KMA Holding, Inc. operates in the healthcare sector, specifically within the medical instruments and supplies industry. Originally named Macada Holding, Inc., the company rebranded to KMA Holding, Inc. in March 2011. KMA Holding focuses on the manufacturing and distribution of human and pet home medical test kits, along with emergency response mobile hospital units. These kits facilitate the detection of various illnesses, including cancer, through the analysis of blood, saliva, urine, hair, and other substances. The company’s product line includes home screening medical detection test kits for drugs of abuse, sexually transmitted diseases, infectious diseases, tumor markers, and fertility. KMA Holding also offers pet home medical test kits for conditions like cancer, diabetes, and Lyme disease. Furthermore, the company provides emergency medical response mobile hospital units, designed to offer temporary emergency life support, medical and pharmaceutical products and services, and communication via secured wireless technology. KMA Holding aims to provide accessible and rapid diagnostic solutions for both humans and pets, along with mobile medical infrastructure for emergency situations.

Qué hacen

  • Manufactures home medical test kits for humans.
  • Manufactures home medical test kits for pets.
  • Provides home screening medical detection test kits for various conditions.
  • Offers emergency medical response mobile hospital units.
  • Provides temporary emergency life support through mobile units.
  • Offers medical and pharmaceutical products and services.
  • Provides communication via secured wireless technology within its mobile units.

Modelo de Negocio

  • Manufacturing and selling home medical test kits directly to consumers.
  • Providing emergency medical response mobile hospital units to healthcare providers and government agencies.
  • Generating revenue through the sale of medical and pharmaceutical products and services within the mobile units.

Contexto de la Industria

KMA Holding, Inc. operates within the medical instruments and supplies industry, a segment experiencing growth due to increasing demand for home healthcare solutions and point-of-care diagnostics. The market is characterized by technological advancements, stringent regulatory requirements, and intense competition. Companies like BRSYF (Bristol Myers Squibb), CYBQY (CyboSoft General Cybernetics), EVGRF (Evergreen Sustainable Development), GNFTF (Genenta Science), and MFCSF (Medifocus) represent the competitive landscape. KMA Holding's focus on home testing kits and mobile hospital units positions it within a niche market, requiring effective marketing and distribution strategies to capture market share.

Clientes Clave

  • Individual consumers seeking convenient home medical testing.
  • Pet owners looking for early detection of diseases in their pets.
  • Hospitals and clinics requiring mobile emergency medical facilities.
  • Government agencies needing mobile medical support during emergencies.
Confianza de la IA: 69% Actualizado: 16 mar 2026

Finanzas

Gráfico e información

Precio de la acción de KMA Holding, Inc. (MCDA): Price data unavailable

Últimas noticias

No hay noticias recientes disponibles para MCDA.

Consenso de analistas

Calificación de Consenso

Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para MCDA.

Objetivos de Precios

Análisis del precio objetivo de Wall Street para MCDA.

MoonshotScore

50/100

¿Qué significa esta puntuación?

El MoonshotScore califica el potencial de crecimiento de MCDA en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.

Liderazgo: Ronald Ritter

CEO

Ronald Ritter serves as the Chief Executive Officer of KMA Holding, Inc. His background includes experience in the healthcare and medical device industries. Ritter has held various leadership positions, focusing on strategic planning, product development, and market expansion. His expertise lies in identifying market opportunities and driving business growth through innovative solutions. Ritter's leadership aims to position KMA Holding as a key player in the home medical testing and mobile healthcare sectors.

Historial: Under Ronald Ritter's leadership, KMA Holding, Inc. has focused on expanding its product line of home medical test kits and mobile hospital units. Key milestones include the development of new diagnostic tests and the establishment of strategic partnerships. Ritter has overseen efforts to enhance the company's market presence and improve operational efficiency. However, specific financial achievements and performance metrics under his tenure are not readily available.

Información del mercado OTC de MCDA

The OTC Other tier represents the lowest tier of the OTC market, indicating that KMA Holding, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited financial disclosure and may be subject to greater regulatory scrutiny. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies face fewer listing requirements, resulting in increased risk and potential for speculative trading. Investors should exercise caution and conduct thorough due diligence before investing in OTC Other stocks.

Riesgo de Shell: Este valor ha sido marcado por riesgo de shell por OTC Markets.
  • Nivel OTC: OTC Other
  • Estado de divulgación: Unknown
Liquidez: Liquidity for stocks on the OTC Other tier is typically very low. Bid-ask spreads can be wide, making it difficult to buy or sell shares at desired prices. Trading volume is often minimal, which can lead to significant price fluctuations and increased volatility. Executing large trades may be challenging due to the limited number of buyers and sellers. Investors should be prepared for potential difficulties in entering and exiting positions in MCDA.
Factores de riesgo OTC:
  • Limited Financial Disclosure: Lack of comprehensive financial reporting increases the difficulty of assessing the company's financial health.
  • Low Liquidity: Minimal trading volume and wide bid-ask spreads can result in price volatility and difficulty in executing trades.
  • Shell Risk: The detection of shell risk indicates potential issues with the company's structure and operations.
  • Regulatory Scrutiny: OTC Other companies are subject to greater regulatory scrutiny due to their lower listing standards.
  • Speculative Trading: Increased potential for speculative trading and market manipulation.
Lista de verificación de diligencia debida:
  • Verify the company's legal registration and compliance status.
  • Review available financial statements and assess the company's financial health.
  • Investigate the background and experience of the company's management team.
  • Evaluate the company's business model and competitive landscape.
  • Assess the company's regulatory risks and compliance requirements.
  • Monitor trading volume and price volatility.
  • Consult with a qualified financial advisor.
Señales de legitimidad:
  • Established history of operations since 2000.
  • Focus on manufacturing and distributing tangible products (home medical test kits and mobile hospital units).
  • Presence in the healthcare sector, addressing a real market need.
  • CEO with experience in the healthcare and medical device industries.
  • Company headquarters located in Pompano Beach, Florida.

Acciones de KMA Holding, Inc.: Preguntas Clave Respondidas

¿Cuáles son los factores clave para evaluar MCDA?

KMA Holding, Inc. (MCDA) actualmente tiene una puntuación IA de 50/100, indicando puntuación moderada. Fortaleza clave: Niche market focus on home medical testing and mobile hospital units.. Riesgo principal a monitorear: Potential: Stringent regulatory requirements and compliance costs impacting profitability.. Esto no es asesoramiento financiero.

¿Qué es el MoonshotScore de MCDA?

MCDA actualmente puntúa 50/100 (Grado C) en el MoonshotScore, lo que sugiere calificación moderada. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.

¿Con qué frecuencia se actualizan los datos de MCDA?

Los precios de MCDA se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.

¿Qué dicen los analistas sobre MCDA?

La cobertura de analistas para MCDA incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.

¿Cuáles son los riesgos de invertir en MCDA?

Las categorías de riesgo para MCDA incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Stringent regulatory requirements and compliance costs impacting profitability.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.

¿Cuál es la relación P/E de MCDA?

La relación P/E para MCDA compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.

¿Está MCDA sobrevalorada o infravalorada?

Determinar si KMA Holding, Inc. (MCDA) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.

¿Cuál es el rendimiento por dividendo de MCDA?

KMA Holding, Inc. (MCDA) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.

Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.

Recursos Oficiales

Análisis actualizado el Puntuación de IA actualizada diariamente
Fuentes de Datos y Metodología
Datos de mercado proporcionados por Financial Modeling Prep y Yahoo Finance. Análisis de IA por algoritmos propietarios de Stock Expert AI. Indicadores técnicos mediante cálculos estándar de la industria. Última actualización: .

Datos proporcionados solo con fines informativos.

Notas de análisis
  • Limited financial data available due to OTC listing.
  • AI analysis pending for further insights.
Fuentes de datos

Popular Stocks